ANKRD30A: A Potential Drug Target and Biomarker (G91074)

Target Name: ANKRD30A

NCBI ID: G91074

ANKRD30A

ANKRD30A: A Potential Drug Target and Biomarker

Ankyrin repeat domains (ANKs) are a type of gene transcription factor that play a crucial role in the regulation of various cellular processes. ANKs are characterized by the presence of a characteristic repeat sequence, which is usually a repeated sequence of the amino acids Asp, Asn, Asp, or Asn. ANKs are found in various cell types and are involved in the regulation of protein synthesis, cell signaling, and chromatin structure. One of the ANKs, ANKRD30A, has been identified as a potential drug target and biomarker for various diseases.

The ANKRD30A gene is located on chromosome 11p and encodes a protein that consists of 214 amino acids. The protein has a molecular weight of 21.1 kDa and a calculated pI of 5.8 nM. ANKRD30A is primarily expressed in the brain and is also found in other tissues , including the heart, skeletal muscles, and kidneys. The protein is involved in various cellular processes, including cell signaling, protein synthesis, and chromatin regulation.

One of the unique features of ANKRD30A is its ability to form a complex with other proteins, including the neurotransmitter GABA. This interaction between ANKRD30A and GABA receptors suggests that ANKRD30A may play a role in the regulation of neurotransmitter signaling. Additionally, ANKRD30A has been shown to interact with the protein brain-derived neurotrophic factor (BDNF), which is a protein that promotes brain health and is involved in the development and treatment of various neurological disorders.

The ANKRD30A gene has also been implicated in the development and progression of various diseases. For example, ANKRD30A has been shown to be overexpressed in various cancer types, including breast, ovarian, and prostate cancer. This overexpression is thought to contribute to the development of cancer-related symptoms and the progression of the disease. Additionally, ANKRD30A has also been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The ANKRD30A protein has been shown to interact with the protein tau, which is a component of neurodegenerate diseases. This interaction suggests that ANKRD30A may play a role in the development and progression of neurodegenerative diseases.

In addition to its potential role as a drug target, ANKRD30A has also been identified as a potential biomarker for various diseases. The ANKRD30A protein has been shown to be expressed in various biological fluids, including blood, urine, and brain. Additionally, the protein has been shown to be decreased in various diseases, including cancer and neurodegenerative diseases. This decrease in ANKRD30A protein levels is thought to contribute to the development and progression of these diseases.

The ANKRD30A gene has also been the subject of research to investigate its potential drug resistance. Studies have shown that ANKRD30A can be overexpressed in various cancer types and that the overexpression is associated with poor prognosis. Additionally, studies have also shown that ANKRD30A can be a drug resistance gene in cancer. This suggests that ANKRD30A may be a useful target for cancer therapies that are resistant to traditional cancer treatments.

In conclusion, ANKRD30A is a gene transcription factor that is involved in various cellular processes and has been implicated in the development and progression of various diseases. The ANKRD30A protein has also been shown to be a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of ANKRD30A in disease progression and to develop effective therapies that target this protein.

Protein Name: Ankyrin Repeat Domain 30A

The "ANKRD30A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD30A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets